FDA approves Strensiq (asfotase alfa) to treat hypophosphatasia- Alexion

Alexion Pharmaceuticals has announced that the FDA has approved Strensiq (asfotase alfa) for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP). Asfotase alfa, an enzyme replacement therapy (ERT), is the first therapy approved in the US for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare metabolic disease in which patients experience on multiple systemic effects leading to debilitating or life-threatening complications.

Comment: Strensiq is approved in the EU, Japan and Canada.